Biotech


  • Ira Spector SFA Therapeutics
    Image attribution tooltip
    Permission granted by Ira Spector SFA Therapeutics
    Profile

    A biotech CEO’s favorite ‘F’ word

    At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.

    By Jan. 26, 2023
  • A brown building with white vertical sign with the Twitter logo
    Image attribution tooltip
    Justin Sullivan/Staff via Getty Images

    With Twitter in flux, pharma is turning to alternative social spaces

    Elon Musk’s takeover of Twitter has upended the ways pharma companies communicate with doctors online. Now new social strategies are emerging.

    By Jan. 26, 2023
  • Johanna Mercier headshot
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Q&A

    Gilead’s commercial chief on why 2023 will be a ‘coming out’ year

    With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.

    By Jan. 26, 2023
  • Lauren Lazar Calcium
    Image attribution tooltip
    Permission granted by Lauren Lazar Calcium
    Podcast

    Woman of the Week: Dr. Lauren Lazar

    As Calcium’s medical director, Lazar is leveraging next-generation innovation to create strategic connections between science and marketing for healthcare brands.

    By Jan. 25, 2023
  • High angle shot of a group of medical practitioners analyzing x-rays on a digital tablet in a hospital.
    Image attribution tooltip
    Stock via Getty Images

    Report reveals murky picture of clinical trial diversity gains

    Data discrepancies between study phases and indications could provide clues about why some trials have better racial and ethnic diversity than others.

    By Alexandra Pecci • Jan. 24, 2023
  • A prescription bottle with white pills and a wooden gavel sit atop a $100 bill showing Benjamin Franklin's face.
    Image attribution tooltip
    Bill Oxford via Getty Images

    Drug price negotiations: 5 key dates to watch

    As the CMS readies its new program for lowering drug costs, these are the moments that will matter most to pharma companies.

    By Kelly Bilodeau • Jan. 23, 2023
  • The headquarters of the FDA, which has recently issued a recall for Teleflex air filters used in hospital respirators.
    Image attribution tooltip
    Sarah Silbiger/Getty Images via Getty Images

    FDA’s 2022 drug approvals fall short of recent norms

    The U.S. agency’s lower number of novel drug approvals followed several controversies surrounding a 2021 Alzheimer’s approval.

    By Alexandra Pecci • Jan. 19, 2023
  • Novavax vaccine
    Image attribution tooltip
    Carsten Koall via Getty Images

    After ‘limping along,’ Novavax sees a path forward

    With a new CEO and a long-term booster strategy, the company believes there’s plenty of room to grow in the COVID-19 vaccine space.

    By Jan. 18, 2023
  • Sean McCarthy, CEO and chairman, CytomX
    Image attribution tooltip
    Permission granted by CytomX
    Q&A

    A Moderna tie-up ushers in new era for CytomX

    The antibody-focused company followed up a tough year with big partnerships to keep the ball rolling.

    By Jan. 18, 2023
  • Talia Cohen-Solal Genetika+
    Image attribution tooltip
    Permission granted by Talia Cohen-Solal WoW
    Podcast

    Woman of the Week: Genetika+’s Talia Cohen Solal

    The CEO is aiming to build a “brain-in-a-dish” to treat all patients for better mental health outcomes.

    By Jan. 18, 2023
  • Futuristic 3D cubes showing DNA base pairs and a double helix.
    Image attribution tooltip
    JuSun via Getty Images

    The M&A hunt is on — here are the prime targets

    Companies with advanced molecular therapies, oncology assets and obesity treatments could be fuel for a dealmaking fire this year.

    By Kelly Bilodeau • Jan. 17, 2023
  • Gene therapy of the DNA cell, low-poly design of a human hand with a syringe and a spiral-shaped chromosome. Blue background.
    Image attribution tooltip

    Ilya/Stock.adobe.com

    Sponsored by Allucent

    Focusing on smaller biotechs to have a big impact on society

    Marcus Delatte discusses how and why he focuses his expertise on counseling smaller companies and mentoring the next generation of technical experts.

    Jan. 17, 2023
  • financial storm
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    How biotechs can weather the market storm

    Execs at JPM sound off on moves companies can make to survive the challenging market conditions.

    By Jan. 13, 2023
  • International Space Station
    Image attribution tooltip
    iStock via Getty Images

    Space — the next frontier in drug development

    Merck, Bristol Myers Squibb and others are taking small R&D steps in space that could lead to giant leaps for patients.

    By Kelly Bilodeau • Jan. 12, 2023
  • M&A handshake
    Image attribution tooltip
    iStock via Getty Images

    Biopharma M&A may get the push it needs in 2023, but with a face lift

    A flurry of recent deals has reinforced forecasts that the long drought is over — circumstances have changed though, and M&A may not be the same.

    By Jan. 12, 2023
  • Claire Aldridge Form Bio
    Image attribution tooltip
    Permission granted by Claire Aldridge Form Bio
    Podcast

    Woman of the Week: Form Bio’s Claire Aldridge

    The chief strategy officer of Form Bio is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.

    By Jan. 11, 2023
  • Hans Schambye Galecto
    Image attribution tooltip
    Permission granted by Hans Schambye
    Q&A // Biotech Spotlight

    Galecto has identified a master switch to reduce fibroid formation

    With expertise surrounding a natural family of proteins and enzymes that can lead to fibrosis, Galecto is exploring the potential to develop cancer treatments.

    By Jan. 11, 2023
  • Kidney
    Image attribution tooltip
    iStock via Getty Images
    Biotech Spotlight

    Chinook Therapeutics nears the finish line in kidney disease

    A company focused on kidney disease, Chinook is growing into a commercial outfit as its lead candidate approaches the market.

    By Jan. 10, 2023
  • A photograph of a Biogen building located in Cambridge, Massachusetts, on Oct. 22, 2015.
    Image attribution tooltip

    Nicolaus Czarnecki/Zuma Press/Newscom

    Making Moves

    C-suite changes at Biogen, Bluebird, Novavax give insight into 2023 business plans

    A breakdown of the most buzzworthy executive changes so far in the new year and how they’re causing ripples in the life sciences industry.

    By Jan. 10, 2023
  • Glass vials with orange caps sit on a pharmaceutical factory production line.
    Image attribution tooltip
    Stock via Getty Images
    Q&A // Biotech Spotlight

    Gracell Biotechnologies’ quest to unlock the CAR-T bottleneck

    The biotech hopes to upend the CAR-T category by cutting manufacturing from weeks to hours and developing a first-line cell therapy.

    By Jan. 9, 2023
  • An aerial view of San Francisco
    Image attribution tooltip
    Stock via Getty Images

    What’s top of mind for industry execs at JPM?

    Leaders in the space reveal the topics that are top of mind as the year’s biggest healthcare conference kicks off next week.

    By Jan. 6, 2023
  • Alzheimer's road
    Image attribution tooltip
    Cemile Bingol via Getty Images

    Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023

    As controversies abound and new drugs rise on the regulatory horizon, this year will be big for Alzheimer’s.

    By Jan. 5, 2023
  • spilled vial
    Image attribution tooltip
    Stock via Getty Images

    Nonprofits are bridging R&D’s valley of death

    How charitable firms such as Advancium are helping to right the market wrongs of drug development.

    By Kelly Bilodeau • Jan. 4, 2023
  • Juliette Han WoW
    Image attribution tooltip
    Permission granted by Juliette Han Cambrian
    Podcast

    Woman of the Week: Cambrian BioPharma’s Juliette Han

    The CFO and COO is advancing moonshot efforts to address aging-related diseases for the "healthspan" company and is helping emerging biotechs bring innovations out of academia.

    By Jan. 4, 2023
  • crystal ball 2023
    Image attribution tooltip
    Stock via Getty Images
    Opinion

    The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences

    A preview of the top trends on the minds of industry and market leaders for the new year.

    By Jan. 3, 2023